Farklı SARS-Cov-2 Varyantları ile Enfekte COVID-19 Hastalarının Klinik Seyirleri, Ölüm Oranları ve Aşı Durumları

Year 2025, Volume: 9 Issue: 2, 210 - 214, 08.08.2025

Tuğçe Ünalan-altıntop , Fikriye Milletli Sezgin , Pelin Onarer , Mustafa Cihangiroğlu , Nilüfer Tali

https://doi.org/10.46332/aemj.1576729

https://izlik.org/JA92TS56UT

Abstract

Amaç: COVID-19 pandemisi sırasında birçok farklı SARS-CoV-2 varyantları ortaya çıkmış ve alfa, beta ve delta varyantları endişe verici varyant olarak kabul edilmiştir. Çalışmamızın amacı alfa, beta ve delta varyantları ile enfekte COVID-19 hastalarının klinik seyir ve aşı durumlarını belirlemektir.

Araçlar veYöntem: Hastaların üst solunum yolları örneklerinde SARS-CoV-2 virüs varlığı ve varyant tipleri Rt-PCR ile saptanmıştır.

Bulgular: Alfa, beta ve delta varyantların ölüm oranları sırasıyla %4.12, %18.43, ve %3.30’dur (p=0.001). Yoğun bakım ihtiyacı alfa varyant için hastaların %3.50’sinde, beta için %18.42’sinde ve delta için % 3.85’inde oluşmuştur (p=0.001). Alfa varyantı ile enfekte hastaların % 2.47’sinde mekanik ventilasyon (MV) ihtiyacı gelişmiş olup, beta enfekte hastaların %13.6’sında ve delta enfekte hastaların % 1.10’unda MV ihtiyacı gelişmiştir (p=0.001). Alfa enfekte hastaların % 49,8’i, beta enfekte hastaların %65.79’u, ve delta enfekte hastaların % 36.81’i tam aşılıdır (p<0.001). m-RNA aşı oranı (% 7.69 ) ve ek aşı oranları delta varyant ile enfekte hastalarda daha yüksektir (p=0.001).

Sonuç: Beta varyant ciddi klinik seyir ve azalmış aşı yanıtı açısından en riskli bulunmuştur. Riskli varyantların yayılımının önlenmesinde küresel halk sağlığı önemleri gereklidir.

Keywords

alfa , beta , delta , SARS-CoV-2 , varyantlar

The Mortality, Clinical Course and Vaccine Status of COVID-19 Patients with Different SARS-Cov-2 Variants

https://izlik.org/JA92TS56UT

Abstract

Purpose: Several SARS-CoV-2 variants have emerged during the COVID-19 pandemic and alpha, beta, and delta variants were declared as variants of concern. Our aim is to determine the clinical course and vaccine status of COVID-19 patients with alpha, beta, and delta variants.

Materials and Methods: SARS-CoV-2 virus and variant determination in upper respiratory swab samples were done by Rt-PCR.

Results: The mortality rates for the alpha, beta, and delta variants were as follows: 4.12 %, 18.43 %, and 3.30 % respectively (p=0.001). Patients who required an intensive care unit (ICU) stay were also different for alpha, beta, and delta variants: 3.50 %, 18.42 %, and 3.85 % respectively (p=0.001). 2.47 % of alpha-infected patients were in need of mechanical ventilation (MV), whereas 13.16 % of beta infected, and 1.10 % of delta infected patients needed MV (p=0.001). 49.8 % of Alpha infected patients, % 65.79 of Beta patients, and 36.81 % of Delta patients were fully vaccinated (p<0.001). The m-RNA vaccination (7.69 %) and booster dose vaccination rate (2.75%) were higher in the delta variant (p=0.001).

Conclusion: Beta variant has been shown to employ the highest possibility for clinical severity and reduced vaccine efficacy. Global public health interventions are needed to avoid the emergence of high risk variants.

Keywords

alpha , beta , delta , SARS-CoV-2 , variants

Ethical Statement

The study was approved by Amasya University Non-interventional Clinical Studies Ethical Committee (Number: 158, Date: 02.12.2021).

Supporting Institution

None.

Thanks

None.

References

• 1. World Health Organization (WHO). COVID-19: WHO European Region Quarterly Operational Update. https://www.who.int/andorra/publications/m/item/covid-19-who-european-region-quarterly-operational-update-fourth-quarter-2022-weeks-40-52-october-december-2022. Access date 30 March, 2023.
• 2. Alimohamadi Y, Sepandi M, Taghdir M, Hosamirudsari H. Determine the most common clinical symptoms in COVID-19 patients: a systematic review and meta-analysis. J Prev Med Hyg. 2020;61(3):304-312.
• 3. Ramesh S, Govindarajulu M, Parise RS, et al. Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy. Vaccines. 2021;9(10):1195.
• 4. World Health Organization (WHO). Interim recommendations for use of the Pfizer–BioNTech COVID-19 vaccine, BNT162b2, under Emergency Use Listing. https://iris.who.int/bitstream/handle/10665/361720/WHO-2019-nCoV-vaccines-SAGE-recommendation-BNT162b2-2022.2-eng.pdf?sequence=1. Access date 30 March, 2023.
• 5. World Health Organization (WHO). Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: background document to the WHO interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac. https://iris.who.int/bitstream/handle/10665/341455/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-background-2021.1-eng.pdf?sequence=1. Access date 30 March, 2023.
• 6. McLean G, Kamil J, Lee B, et al. The impact of evolving SARS-CoV-2 mutations and variants on COVID-19 vaccines. MBio. 2022;13(2):02979-21.
• 7. COVID-19 Vaccine Breakthrough Infections Reported to CDC- United States. MMWR Morb Mortal Wkly Rep. 2021;70(21):792-793.
• 8. Abu-Raddad LJ, Chemaitelly H, Ayoub HH, et al. Severity, criticality, and fatality of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Beta variant. Clinical Infectious Diseases. 2022;75(1): 1188-1191.
• 9. Zhao S, Peng Z, Wang MH. A tentative assessment of the changes in transmissibility and fatality risk associated with Beta SARS-CoV-2 variants in South Africa: an ecological study. Pathogens and Global Health. 2022;116(3):137-139.
• 10. Ciuffreda L, Alcoba-Florez J, Lorenzo-Salazar JM, et al. Association of the Delta SARS-CoV-2 variant with 28-day hospital mortality between December 2020 and September 2021. J. Infect. 2022;85(1):90-122.
• 11. Zhao S, Lou J, Cao L, et al. Differences in the case fatality risks associated with SARS-CoV-2 Delta and non-Delta variants in relation to vaccine coverage: An early ecological study in the United Kingdom. Infect Genet Evol. 2022;97:105162.
• 12. Zhang J-j, Dong X, Liu G-h, Gao Y-d. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clinical reviews in allergy & immunology. 2023;64(1):90-107.
• 13. Planas D, Bruel T, Grzelak L, et al. Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies. Nat. Med. 2021;27(5):917-924.
• 14. Kislaya I, Rodrigues EF, Borges V, et al. Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with Delta and Alpha variants. Emerg. Infect. Dis. 2022;28(2):331.
• 15. Ai J, Guo J, Zhang H, et al. Cellular basis of enhanced humoral immunity to SARS-CoV-2 upon homologous or heterologous booster vaccination analyzed by single-cell immune profiling. Cell Discovery. 2022;8(1):114.
• 16. Lv J, Wu H, Xu J, Liu J. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infect. Dis. Poverty. 2022;11(1):53.
• 17. Zhao Z, Cui T, Huang M, et al. Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants. Emerg. microbes & infect. 2022;11(1):829-840.
• 18. Xu J, Lan X, Zhang L, et al. The effectiveness of the first dose COVID-19 booster vs. full vaccination to prevent SARS-CoV-2 infection and severe COVID-19 clinical event: a meta-analysis and systematic review of longitudinal studies. Frontiers in Public Health. 2023;11:1165611.